OECD Home › Science and technology › Publications & Documents › Meetings / Conferences / Agendas
Meetings / Conferences / Agendas
This workshop brought together a wide range of stakeholders, including officials of regulatory agencies, representatives of relevant regional or international organizations, researchers, patients’ organizations and representative from industry.
The main objective of the Workshop on the Safety of Manufactured Nanomaterials was to determine the “state-of–the–art” for the safety assessment of manufactured nanomaterials with a particular focus on identifying future needs for risk assessment within a regulatory context.
The OECD Workshop on the Globalisation of Production, to be held in Paris on 15-16/11/2005, aims to examine some of the major challenges related to measuring and analysing the impact of the globalisation of production on employment, productivity and economic growth
The OECD’s Chemicals Committee held a Special Session on the Potential Implications of Manufactured Nanomaterials for Human Health and Environmental Safety, 7th June 2005.
Biological resources are the foundation of all biological sciences research. They provide the source material for scientific investigation, leading to many of the discoveries on which biotechnology is founded.
English, , 123kb
Rapporteurs' report of the Conference on Biotechnology for Infectious Diseases: Addressing the Global Needs, held in Lisbon, Portugal on - 7-9 October 2002.
The objective of the Conference was to bring together a diverse group of participants for a constructive dialogue on the underlying science for assessing transgenic organisms in the environment. The emphasis was on transgenic crops because these ...
The following are the key activities under the Working Party on Biotechnology (WPB).
Regulatory Developments in Xenotransplantation in Italy.
English, , 450kb
This report examines ways in which governments can stimulate the supply of venture capital for innovative firms. Proceedings of the 1995 ad hoc meeting of experts on venture capital.